BR112012011230A2 - fatores de risco e previsão de infarto do miocárdio - Google Patents

fatores de risco e previsão de infarto do miocárdio

Info

Publication number
BR112012011230A2
BR112012011230A2 BR112012011230A BR112012011230A BR112012011230A2 BR 112012011230 A2 BR112012011230 A2 BR 112012011230A2 BR 112012011230 A BR112012011230 A BR 112012011230A BR 112012011230 A BR112012011230 A BR 112012011230A BR 112012011230 A2 BR112012011230 A2 BR 112012011230A2
Authority
BR
Brazil
Prior art keywords
myocardial infarction
individual
prediction
risk factors
risk
Prior art date
Application number
BR112012011230A
Other languages
English (en)
Inventor
Aram S Adourian
Pieter Muntendam
Xiaohong Li
Yu Guo
Original Assignee
Bg Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bg Medicine Inc filed Critical Bg Medicine Inc
Publication of BR112012011230A2 publication Critical patent/BR112012011230A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

fatores de risco e previsão de infarto do miocárdio. biomarcadores e métodos são revelados para diagnóstico do risco de um infarto do miocárdio em um indivíduo através da medição dos níveis de um conjunto de biomarcadores em uma amostra de um indivíduo. uma classificação de risco é calculada para o individuo através da ponderação dos níveis medidos dos biomarcadores. a classificação de risco então é usada para identificar se o indivíduo é provável de sofrer um infarto do miocárdio. ainda, são revelados estojos que incluem um conjunto de reagentes para medir especificamente níveis de biomarcadores em uma amostra de um indivíduo.
BR112012011230A 2009-11-13 2010-11-15 fatores de risco e previsão de infarto do miocárdio BR112012011230A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26115509P 2009-11-13 2009-11-13
PCT/US2010/056711 WO2011060361A1 (en) 2009-11-13 2010-11-15 Risk factors and prediction of myocardial infarction

Publications (1)

Publication Number Publication Date
BR112012011230A2 true BR112012011230A2 (pt) 2016-04-05

Family

ID=43431941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011230A BR112012011230A2 (pt) 2009-11-13 2010-11-15 fatores de risco e previsão de infarto do miocárdio

Country Status (13)

Country Link
US (1) US9274126B2 (pt)
EP (2) EP2568294B1 (pt)
JP (1) JP5728488B2 (pt)
KR (1) KR20120101064A (pt)
CN (1) CN102812359A (pt)
AU (1) AU2010319290A1 (pt)
BR (1) BR112012011230A2 (pt)
CA (1) CA2780301A1 (pt)
EA (1) EA201290311A1 (pt)
IL (1) IL219554A0 (pt)
MX (1) MX2012005385A (pt)
WO (1) WO2011060361A1 (pt)
ZA (1) ZA201203422B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
CN104198712A (zh) * 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
US8765479B1 (en) * 2011-03-13 2014-07-01 Atherotech, Inc. Methods for determining the risk of coronary heart disease and clinical manifestations of coronary heart disease
JP2014523533A (ja) * 2011-07-07 2014-09-11 スクリップス ヘルス 心血管障害を分析する方法及びその用途
US20130244892A1 (en) * 2012-02-12 2013-09-19 Aram S. Adourian Risk Factors and Prediction of Adverse Events
WO2013169890A1 (en) * 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
CN104737170A (zh) * 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
RU2521322C1 (ru) * 2013-02-12 2014-06-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Способ оценки прогрессирования атерогенности при ишемической болезни сердца
US10278624B2 (en) * 2013-05-23 2019-05-07 Iphenotype Llc Method and system for maintaining or improving wellness
KR101660328B1 (ko) 2014-01-14 2016-09-27 한국과학기술연구원 심혈관 질환 진단용 바이오 마커
WO2015140317A1 (en) * 2014-03-21 2015-09-24 Sanofi New markers for the assessment of the risk for development of a cardiovascular disorder
US11373189B2 (en) 2014-03-27 2022-06-28 EMC IP Holding Company LLC Self-learning online multi-layer method for unsupervised risk assessment
EP3204881B1 (en) 2014-11-14 2021-05-26 Zoll Medical Corporation Medical premonitory event estimation
CN104606684B (zh) * 2015-01-13 2017-07-07 南方医科大学南方医院 Ceacam1作为筛选治疗心肌严重缺血损伤的药物的靶标及其应用
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US20160260047A1 (en) * 2015-03-03 2016-09-08 BetterWorks Systems, Inc. Monitoring individual and aggregate progress of multiple team members
KR101791153B1 (ko) 2015-04-17 2017-10-30 한국과학기술연구원 급성 관상동맥 증후군 질환 진단용 다중 생체 대사체 플랫폼
EP3298402A1 (en) * 2015-05-18 2018-03-28 The University of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
EP3391053B1 (en) * 2015-12-17 2020-02-26 Roche Diagnostics GmbH Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he 4) and related uses
US10546102B2 (en) * 2016-01-18 2020-01-28 International Business Machines Corporation Predictive analytics work lists for healthcare
JP2019523431A (ja) * 2016-07-21 2019-08-22 クリーヴランド ハートラブ，インコーポレイテッド Ｈｄｌ関連タンパク質のバイオマーカーパネル検出
US10839962B2 (en) * 2016-09-26 2020-11-17 International Business Machines Corporation System, method and computer program product for evaluation and identification of risk factor
CN106570346B (zh) * 2016-11-14 2020-02-18 京东方科技集团股份有限公司 生理状况评估因子确定方法、生理状况评估因子确定系统
KR102003309B1 (ko) 2016-12-05 2019-07-25 한국과학기술연구원 대사체 및 임상지표를 활용한 관상동맥 심장질환 진단용 키트 및 기초 정보 제공 방법
CN107133475B (zh) * 2017-05-10 2020-09-29 浙江省立同德医院 一种中药注射剂不良反应高危患者模式识别方法
CN107102152B (zh) * 2017-05-17 2019-04-23 中国医学科学院基础医学研究所 尿液中心肌梗死的蛋白标志物及其在诊断和预后中的用途
CN109374901B (zh) * 2018-09-30 2021-08-27 山东大学齐鲁医院 一种心肌梗死预后风险指数检测装置及心肌梗死预后预警模型的建立方法
JP7470933B2 (ja) * 2019-02-20 2024-04-19 フンダシオ インスティテュート ディンベスティガシオ エン シエンシエス デ ラ サリュ ジャーマンス トライアス アイ プジョル ショックを患う患者における死亡リスクを予測するｉｎ ｖｉｔｒｏでの方法
CN112289443A (zh) * 2020-07-14 2021-01-29 山东大学齐鲁医院 一种基于生物标志物的急性心血管事件风险评估系统
CN115910365B (zh) * 2022-11-16 2024-02-13 华中科技大学同济医学院附属同济医院 Eos-CRSwNP术前难治性评估模型的构建方法及预测系统

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3445010A1 (de) 1984-12-10 1986-06-19 Boehringer Mannheim Gmbh Kontroll- bzw. eichserum fuer die lipid-diagnostik
US4945040A (en) 1988-02-29 1990-07-31 Arch Development Corporation Immunoassay for lipoprotein(a)
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6107045A (en) 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
CN1123771C (zh) * 1996-06-11 2003-10-08 财团法人工业技术研究院 一种急性心肌梗塞检测试剂盒
US7226729B1 (en) 1997-04-01 2007-06-05 Shionogi & Co., Ltd. Method for inhibiting degradation of brain natriuretic peptides
ES2374621T3 (es) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
US7030152B1 (en) 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
ATE298423T1 (de) 1997-10-24 2005-07-15 Shionogi & Co Verfahren zur inhibierung des abbaus von natriuretischen peptiden und verbesserte methode zum bestimmen der natriuretischen peptide
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
WO2003016910A1 (en) 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7524635B2 (en) 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
WO2002089657A2 (en) 2001-05-04 2002-11-14 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
MXPA03004105A (es) 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
US6998241B2 (en) * 2002-09-11 2006-02-14 Kimberly-Clark Worldwide, Inc. Antibody pair screening methods
CA2511680A1 (en) 2002-11-18 2004-06-03 Syn X Pharma, Inc. Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
JP2006527190A (ja) 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
PL1625163T3 (pl) 2003-05-12 2012-01-31 Hoffmann La Roche Sposoby wykrywania proBMP przeciwciałem monoklonalnym wiążącym się z aminokwasami 38-43
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
EP1759214B1 (en) 2004-06-15 2013-04-24 F.Hoffmann-La Roche Ag The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
CA2511269A1 (en) 2004-07-07 2006-01-07 F. Hoffmann-La Roche Ag Multimarker panel based on p1gf for diabetes type 1 and 2
US7749729B2 (en) 2004-07-19 2010-07-06 University Of Washington Methods for assessing the risk for development of cardiovascular disease
US7482174B2 (en) 2004-09-09 2009-01-27 University Of Massachusetts Disease markers for early stage atherosclerosis
US7432107B2 (en) 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
US20070042426A1 (en) * 2005-01-28 2007-02-22 Kiernan Urban A Biomarkers and assays for myocardial infarction
ATE444491T1 (de) 2005-05-20 2009-10-15 Germediq Forsch & Entw Ges Mbh Verfahren zur bestimmung von kardiovaskulären risikofaktoren
EP1731910A1 (en) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
CA2613204A1 (en) 2005-06-29 2007-01-11 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of acute coronary syndrome
EP1816477A1 (en) 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing
WO2007106466A2 (en) 2006-03-11 2007-09-20 The Board Of Trustees Of The Leland Stanford Junior University Beta-2 microglobulin as a biomarker for peripheral artery disease
ATE470862T1 (de) 2006-03-24 2010-06-15 Hoffmann La Roche Vorrichtung und verfahren zur unterscheidung zwischen akuter und chronischer myokardial- nekrose bei symptomatischen patienten
WO2007124439A2 (en) 2006-04-21 2007-11-01 Rules-Based Medicine, Inc. Diagnosis of stroke using metalloproteinase or transaminase
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
US7972794B2 (en) 2006-07-18 2011-07-05 Quest Diagnostics Investments Incorporated Oxidized apoA-I determination by mass spectrometry
EP1882945A1 (en) 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath
EP1887361A1 (en) 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
EP1890153A1 (en) 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
WO2008057806A1 (en) 2006-11-01 2008-05-15 Vermillion, Inc. A panel of biomarkers for peripheral arterial disease
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
US8124415B2 (en) 2006-12-14 2012-02-28 National Research Council Of Canada Method and test for blood serum component analysis
CA2710286A1 (en) 2006-12-22 2008-07-03 Aviir, Inc. Two biomarkers for diagnosis and monitoring of atherosclerotic cardiovascular disease
US20110045514A1 (en) 2007-10-10 2011-02-24 Bg Medicine, Inc. Methods for detecting major adverse cardiovascular and cerebrovascular events
JP2011501113A (ja) 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比
EP2265950B1 (en) * 2008-03-05 2019-01-23 Axela Inc. Detection of biomarkers and biomarker complexes
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
US7939287B2 (en) 2008-05-14 2011-05-10 The Regents Of The University Of California Methods of identifying a subject having or at risk of having or developing coronary artery disease

Also Published As

Publication number Publication date
US20110137131A1 (en) 2011-06-09
WO2011060361A1 (en) 2011-05-19
EP2499489B1 (en) 2015-01-07
EP2568294A1 (en) 2013-03-13
ZA201203422B (en) 2014-10-29
EP2568294B1 (en) 2015-01-07
JP5728488B2 (ja) 2015-06-03
EP2499489A1 (en) 2012-09-19
KR20120101064A (ko) 2012-09-12
CN102812359A (zh) 2012-12-05
MX2012005385A (es) 2012-09-12
EA201290311A1 (ru) 2012-12-28
IL219554A0 (en) 2012-06-28
US9274126B2 (en) 2016-03-01
JP2013511047A (ja) 2013-03-28
AU2010319290A1 (en) 2012-05-24
CA2780301A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
BR112012011230A2 (pt) fatores de risco e previsão de infarto do miocárdio
MX2020004617A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
BR112012019542A2 (pt) "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit"
EA201370063A1 (ru) Фосфолипидом рака
IN2015DN01855A (pt)
BR112013003391B8 (pt) Método para diagnosticar câncer pancreático em um indivíduo
IN2014DN04226A (pt)
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
WO2012096545A3 (ko) 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
EP2566983A4 (en) SERIAL ANALYSIS OF BIOMARKERS FOR THE DIAGNOSIS OF A DISEASE
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
BR112012031444A2 (pt) método, arranjo e uso do mesmo
WO2012050365A3 (ko) 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
MX2013004230A (es) Uso de compuestos mejoradores de señal en deteccion de electroquimioluminiscencia.
BR112015014232A2 (pt) lesão renal aguda
BR112012028283A2 (pt) método de determinação de tolerância a transplante de rim
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
NZ605561A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer
BR112013025287A2 (pt) ensaios com receptores de esteroide para detectar células tumorais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]